Reasons for guideline non-compliance for empiric therapy of pneumonia
| Total cases | CAP (n=87) | HAP (n=39) | VAP (n=11) | ASP (n=20) |
| Empiric regimen not aligning with guidelines | 39 (45%) | 23 (59%) | 5 (45%) | 15 (75%) |
| Did not include atypical coverage | 18 (46%) | – | – | – |
| Not recommended by IDSA | 10 (26%) | 13 (57%) | – | – |
| Added vancomycin unnecessarily | 2 (5%) | – | – | – |
| No beta-lactam included | 4 (10%) | 2 (9%) | – | – |
| Did not include MRSA* coverage | – | 6 (26%) | 2 (40%) | - |
| Other | 5 (13%) | 2 (9%) | 3 (60%) | – |
*Local MRSA incidence: 27%.
ASP, aspiration pneumonia; CAP, community-acquired pneumonia; HAP, hospital-acquired pneumonia; IDSA, Infectious Diseases Society of America; MRSA, methicillin-resistant Staphylococcus aureus; VAP, ventilator-associated pneumonia.